A call for a value based approach to laboratory medicine funding

Clinical Biochemistry

Volumn 48, Issue 13-14, 2015, Pages 823-826

  St John, A ^a   Edwards, G ^b   Fisher, S ^c   Badrick, T ^d   Callahan, J ^e   Crothers, J ^f  

^a Australian Government Australian Research Council   (Australia)

^b St John of God Medical Centre   (Australia)

^c The Centre for International Economics   (Australia)

^d Royal College of Pathologists of Australasia   (Australia)

^e SOUTHERN HEALTH   (Australia)

^f Abbott Diagnostics Division   (Australia)

Author keywords

Economics; Funding model; Over testing; Value of pathology

Indexed keywords

ECONOMICS; HEALTH CARE PLANNING; HOSPITAL LABORATORY; HUMAN; PATHOLOGY;

HEALTH PLANNING GUIDELINES; HUMANS; LABORATORIES, HOSPITAL; PATHOLOGY;

EID: 84952983123     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.07.024     Document Type: Editorial

References (24)

1. Porter M.E., Teisberg E.O. Redefining Health Care: Creating Value-based Competition on Results 2006, xvii. Harvard Business School Press, Boston, Massachusetts, (506 pages).
2. Australian Bureau of Statistics, Cat. No. 6401.0 Consumer Price Index, Australia, CPI: All Groups. Index Numbers and Percentage Changes. 2013.
3. Tideman P.A., Tirimacco R., Senior D.P., Setchell J.J., Huynh L.T., Tavella R., et al. Impact of a regionalised clinical cardiac support network on mortality among rural patients with myocardial infarction. Med. J. Aust. 2014, 200:157-160.
4. National health service Whole system demonstrator programme: an overview of telecare and telehealth (Accessed 10 May, 2014). http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_100946.
5. Bell D.A., Hooper A.J., Edwards G., Southwell L., Pang J., van Bockxmeer F.M., et al. Detecting familial hypercholesterolaemia in the community: impact of a telephone call from a chemical pathologist to the requesting general practitioner. Atherosclerosis 2014, 234:469-472.
6. Stecker E.C., Schroeder S.A. Adding value to relative-value units. N. Engl. J. Med. 2013, 369:2176-2179.
7. Chien A.T., Rosenthal M.B. Medicare's physician value-based payment modifier-will the tectonic shift create waves?. N. Engl. J. Med. 2013, 369:2076-2078.
8. Siontis K.C., Siontis G.C., Contopoulos-Ioannidis D.G., Ioannidis J.P. Diagnostic tests often fail to lead to changes in patient outcomes. J. Clin. Epidemiol. 2014, 67:612-621.
9. Ferrante di Ruffano L., Hyde C.J., McCaffery K.J., Bossuyt P.M., Deeks J.J. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ 2012, 344:e686.
10. Horvath A.R., Lord S.J., StJohn A., Sandberg S., Cobbaert C.M., Lorenz S., et al. From biomarkers to medical tests: the changing landscape of test evaluation. Clin. Chim. Acta 2014, 427:49-57.
11. Price C.P., St John A. Anatomy of a value proposition for laboratory medicine. Clin. Chim. Acta 2014, 436C:104-111.
12. Excellence NIfHaC About clinical guidelines (Accessed 20 March, 2015). http://www.nice.org.uk/aboutnice/whatwedo/aboutclinicalguidelines/about_clinical_guidelines.jsp.
13. Map of Medicine Map pathways (Accessed 27 March, 2015). http://mapofmedicine.com/how-we-can-help/.
14. Bilinski K., Boyages S. Evidence of overtesting for vitamin D in Australia: an analysis of 4.5years of medicare benefits schedule (MBS) data. BMJ Open 2013, 3.
15. Driskell O.J., Holland D., Hanna F.W., Jones P.W., Pemberton R.J., Tran M., Fryer A.A. Inappropriate requesting of glycated hemoglobin (hb a1c) is widespread: assessment of prevalence, impact of national guidance, and practice-to-practice variability. Clin. Chem. 2012, 58:906-915.
16. Si D., Bailie R., Wang Z., Weeramanthri T. Comparison of diabetes management in five countries for general and indigenous populations: an internet-based review. BMC Health Serv. Res. 2010, 10:169.
17. Zhi M., Ding E.L., Theisen-Toupal J., Whelan J., Arnaout R. The landscape of inappropriate laboratory testing: a 15-year meta-analysis. PLoS ONE 2013, 8:e78962.
18. PricewaterhouseCoopers International Review of Pathology Funding Arrangements, Prepared for the Department of Health and Ageing 2010.
19. Garrison L.P., Bresnahan B.W., Higashi M.K., Hollingworth W., Jarvik J.G. Innovation in diagnostic imaging services: assessing the potential for value-based reimbursement. Acad. Radiol. 2011, 18:1109-1114.
20. Raab G.G., Parr D.H. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology-part 1: issues in medical device assessment. J. Am. Coll. Radiol. 2006, 3:694-702.
21. Raab G.G., Parr D.H. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology-part 2: coverage. J. Am. Coll. Radiol. 2006, 3:772-777.
22. Raab G.G., Parr D.H. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology-part 3: payment. J. Am. Coll. Radiol. 2006, 3:842-850.
23. Ramsey S.D., Veenstra D.L., Garrison L.P., Carlson R., Billings P., Carlson J., Sullivan S.D. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. Am. J. Manag. Care 2006, 12:197-202.
24. Fang C., Otero H.J., Greenberg D., Neumann P.J. Cost-utility analyses of diagnostic laboratory tests: a systematic review. Value Health 2011, 14:1010-1018.